Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02665221 · ClinicalTrials.gov registry record · Phase 4
Single Center, Open Label, Study of Preparation H on Erythema in Relapsing MS Patients Treated With PLEGRIDY
A Phase 4 study, sponsored by NYU Langone Health.
- Terminated
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT02665221 is a Phase 4 study that was terminated before completion, run by NYU Langone Health. The registered enrollment target is 30 participants.
The verdict
NCT02665221, a Phase 4 study, was terminated before completion, sponsored by NYU Langone Health.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
The primary purpose of this single center, randomized, open label study in relapsing Multiple Sclerosis (MS) patients on PLEGRIDY (peginterferon beta-1a) is to assess the effect of Preparation H (phenylephrine) Maximum Strength Cream compared to no topical treatment of injection site erythema after PLEGRIDY injection.
Interventions
- OTHER No Treatment Arm
- DRUG Topical Preparation H arm
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2015-07 |
| Est. Completion | 2016-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02665221
The ClinicalTrials.gov registry entry for NCT02665221 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which No Treatment Arm is the first listed.
NCT02665221 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02665221 about?
NCT02665221 is a clinical study titled "Single Center, Open Label, Study of Preparation H on Erythema in Relapsing MS Patients Treated With PLEGRIDY". The primary purpose of this single center, randomized, open label study in relapsing Multiple Sclerosis (MS) patients on PLEGRIDY (peginterferon beta-1a) is to assess the effect of Preparation H (phenylephrine) Maximum Strength Cream compared to no topical treatment of injection site erythema after ...
What is the current status of trial NCT02665221?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2015-07. Estimated completion is 2016-09.
What interventions are being tested in trial NCT02665221?
The interventions under investigation include: No Treatment Arm (OTHER), Topical Preparation H arm (DRUG).
Who is sponsoring clinical trial NCT02665221?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.